Table 1.
Characteristics of GWASs in anti-cytomegalovirus IgG levels and the risk of 9 cardiovascular diseases.
| Exposure/outcomes | No. of controls | No. of cases | Sample size | Year of publication | Number of SNPs | Build | Study population |
|---|---|---|---|---|---|---|---|
| Anti-cytomegalovirus IgG levels (Scepanovic et al., 2018) | – | – | 347 | 2018 | 5,278,042 | HG19/GRCh37 | European |
| Atrial fibrillation (Christophersen et al., 2017) | 102,776 | 15,979 | 118,755 | 2017 | 10,719,646 | HG19/GRCh37 | European |
| Coronary artery disease (van der Harst and Verweij, 2018) | 424,528 | 122,733 | 547,261 | 2017 | 7,934,254 | HG19/GRCh37 | European |
| Hypertension (2018) | 359,957 | 1,237 | 361,194 | 2018 | 9,646,741 | HG19/GRCh37 | European |
| Heart failure (2021) | 195,091 | 13,087 | 208,178 | 2021 | 16,380,422 | HG19/GRCh37 | European |
| Peripheral artery disease (2020) | 92,349 | 2,383 | 94,732 | 2020 | 16,152,119 | HG19/GRCh37 | European |
| Pulmonary embolism (2022) | 95,023 | 1,366 | 96,389 | 2020 | 16,152,119 | HG19/GRCh37 | European |
| DVT of lower extremities (2020) | 359,078 | 2,116 | 361,194 | 2018 | 10,544,982 | HG19/GRCh37 | European |
| Rheumatic valve diseases (2020) | 96,273 | 162 | 96,435 | 2020 | 16,152,119 | HG19/GRCh37 | European |
| Non-rheumatic valve diseases (2018) | 359,588 | 1,606 | 361,194 | 2018 | 10,080,950 | HG19/GRCh37 | European |
DVT, deep vein thrombosis; GWASs, genome-wide association studies; SNPs, single-nucleotide polymorphisms.